Compare Enveric Biosciences Inc (ENVB) vs ProShares UltraPro Short QQQ ETF (SQQQ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enveric Biosciences Inc vs ProShares UltraPro Short QQQ ETF — how do they compare? Enveric Biosciences Inc trades at $1.51 (market cap $6.80M), while ProShares UltraPro Short QQQ ETF trades at $32.69 (market cap $2.23B). The key difference: ProShares UltraPro Short QQQ ETF is far larger — about 327.9× Enveric Biosciences Inc's market cap, and Enveric Biosciences Inc is more actively traded (64,867 versus 60,436,012). Which is the better fit depends on your goals — on Pluang, investors hold Enveric Biosciences Inc for 14 Days and ProShares UltraPro Short QQQ ETF for 12 Days on average.
| ENVB | SQQQ | |
|---|---|---|
Market Cap | $6.80M | $2.23B |
Volume | 64,867 | 60,436,012 |
Sector | Health | Leveraged / Inverse |
52-Week High | $10.80 | $89.43 |
52-Week Low | $1.27 | $31.83 |
Typical Hold Time | 14 Days | 12 Days |
Enterprise Value | -$1.49M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENVB trades at $1.495 with a 1.7% daily gain, showing technical bearish signals despite recent earnings beats. The company reported no revenue in 2025 with significant losses (-$8.77M net income), though valuation metrics appear low (EV/EBITDA 0.17, P/B 0.84). Recent news highlights patent approvals and positive preclinical data for non-hallucinogenic therapeutics.
The outlook remains speculative given the lack of revenue and substantial losses, offset by strong analyst support (75% buy rating) and promising drug development progress. Key risks include funding needs and clinical trial outcomes, while institutional sentiment appears cautiously optimistic about long-term pipeline potential.
SQQQ (ProShares UltraPro Short QQQ) trades at $32.08, up 0.79% today, as a 3x leveraged inverse ETF designed to profit from declines in the Nasdaq-100. Technical indicators show a bearish trend with moving averages signaling sell pressure, though oscillators suggest potential near-term oversold conditions. The ETF serves as a hedging tool against tech sector weakness, with recent news highlighting its strategic use alongside long QQQ positions.
Outlook remains tied to Nasdaq-100 performance; further tech sector declines could benefit SQQQ, but leveraged decay and volatility pose significant risks. Investors using SQQQ for hedging should monitor market sentiment and sector-specific catalysts. The ETF's structure makes it unsuitable for long-term holdings due to compounding effects in volatile markets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Enveric Biosciences Inc
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →About ProShares UltraPro Short QQQ ETF
SQQQ is a leveraged inverse ETF that seeks daily investment results, before fees and expenses, that correspond to three times the inverse (-3x) of the daily performance of the Nasdaq-100 Index. It is a tactical trading tool designed for sophisticated investors to profit from or hedge against declines in large-cap technology and growth stocks. Due to its daily reset and the effects of compounding, it is intended for short-term use and carries significant risk if held during periods of high market volatility.
Read more on SQQQ →
